therapies | e-Asfalistiki
Spain: EIB provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases
EIB support to develop breakthrough treatments to address orphan neurodegenerative diseases with high unmet medical needs Focus on Minoryx’s lead asset, leriglitazone, a novel, disease-modifying PPAR-γ agonist Venture debt operation…
EIB signs collaboration with Israel Innovation Authority and €50 million financing agreement with Pluristem to develop therapies for COVID-19 and other unmet medical needs
- European Investment Bank (EIB) backs Pluristem with €50 million of financing, which will help the company to advance the clinical development of its cell therapies and address a number…
